Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;94(11):986–991. doi: 10.1111/j.1349-7006.2003.tb01389.x

Different expression patterns of KIT, EGFR, and HER‐2 (c‐erbB‐2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma

Morio Sawada 1,2, Hitoshi Tsuda 2,✉, Mikihiko Kimura 2, Sanshiro Okamoto 3, Tsunekazu Kita 3, Takahiro Kasamatsu 1, Takuro Yamada 1, Yoshihiro Kikuchi 3, Hideo Honjo 4, Osamu Matsubara 2
PMCID: PMC11160179  PMID: 14611676

Abstract

Uterine carcinosarcoma histologically comprises the components of epithelial and mesenchymal malignancies, and is known to be clinically highly aggressive. To reveal the significance of the expression of tyrosine‐kinase‐receptor‐type oncoproteins in this tumor type, the incidence and distribution of the KIT, EGFR, and HER‐2 (c‐erbB‐2) oncoproteins were immunohistochemically examined in 16 surgically resected cases. For 6 cases, the EGFR and HER‐2 amplifications were also examined by fluorescence in situ hybridization (FISH). In the epithelial component, overexpressions of KIT, EGFR, and HER‐2 were detected in 4 (25%), 5 (31%), and 9 (56%) cases, respectively, whereas these overexpressions in the mesenchymal component were detected in 6 (38%), 8 (50%), and 1 (6%) cases, respectively. KIT and EGFR were co‐overexpressed in the mesenchymal component of 4 cases and in the epithelial component of 2 cases. However, HER‐2 overexpression was mostly detected in the epithelial component only, and tended to occur independently of KIT and/or EGFR overexpression. By FISH, one of the 4 cases with HER‐2 overexpression showed low‐level gene amplification. In two cases with EGFR overexpression, the gain of EGFR alleles and/or polyploidization of chromosome 7 had occurred. The expression patterns of KIT, EGFR, and HER‐2 differed between the epithelial and mesenchymal components, and the regulation of their expression appeared important in the acquisition of mesenchymal metaplasia in uterine carcinosarcoma. Structural and/or numerical alterations of chromosomes might be in part involved in EGFR and/or HER‐2 overexpression in this tumor type.

References

  • 1. Ali S, Wells M. Mixed müllerian tumors of the uterine corpus: a review. Int J Gynecol Cancer 1993; 3: 1–11. [DOI] [PubMed] [Google Scholar]
  • 2. Silverberg SG, Major FJ, Blessing JA, Fetter B, Askin FB, Liao SY, Miller A. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 1990; 9: 1–19. [DOI] [PubMed] [Google Scholar]
  • 3. de Brito PA, Silverberg SG, Orenstein JM. Carcinosarcoma (malignant mixed müllerian (mesodermal) tumor) of the female genital tract: immunohistochemical and ultrastructural analysis of 28 cases. Hum Pathol 1993; 24: 32–42. [DOI] [PubMed] [Google Scholar]
  • 4. Wada H, Enomoto T, Fujita M, Yoshino K, Nakashima R, Kurachi H, Haba T, Wakasa K, Shroyer KR, Tsujimoto M, Hongyo T, Nomura T, Murata Y. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res 1997; 57: 5379–85. [PubMed] [Google Scholar]
  • 5. Gorai I, Yanagibashi T, Taki A, Udagawa K, Miyagi E, Nakazawa T, Hirahara F, Nagashima Y, Minaguchi H. Uterine carcinosarcoma is derived from a single stem cell: an in vitro study. Int J Cancer 1997; 72: 821–7. [DOI] [PubMed] [Google Scholar]
  • 6. Fujii H, Yoshida M, Gong ZX, Matsumoto T, Hamano Y, Fukunaga M, Hruban RH, Gabrielson E, Shirai T. Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res 2000; 60: 4–20. [PubMed] [Google Scholar]
  • 7. McCluggage WG. Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas J Clin Pathol 2002; 55: 321–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Dinh TV, Slavin RE, Bhagavan BS, Hannigan EV, Tiamson EM, Yandell RB. Mixed müllerian tumors of the uterus: a clinicopathologic study. Obstet Gynecol 1989; 74: 388–92. [PubMed] [Google Scholar]
  • 9. Nielsen SN, Podratz KC, Scheithauer BW, O'Brien PC. Clinicopathologic analysis of uterine malignant mixed müllerian tumors. Gynecol Oncol 1989; 34: 372–8. [DOI] [PubMed] [Google Scholar]
  • 10. Podczaski ES, Woomert CA, Stevens CW Jr, Manetta A, Larson JE, Zaino RJ, Mortel R. Management of malignant, mixed mesodermal tumors of the uterus. Gynecol Oncol 1989; 32: 240–4. [DOI] [PubMed] [Google Scholar]
  • 11. Peters WA 3rd, Kumar NB, Fleming WP, Morley GW. Prognostic features of sarcomas and mixed tumors of the endometrium. Obstet Gynecol 1984; 63: 550–6. [PubMed] [Google Scholar]
  • 12. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 37 Suppl 4: S9–15. [DOI] [PubMed] [Google Scholar]
  • 13. Ebert AD, Wechselberger C, Martinez‐Lacaci I, Bianco C, Weitzel HK, Salomon DS. Expression and function of EGF‐related peptides and their receptors in gynecological cancer‐from basic science to therapy. J Recept Signal Transduct Res 2000; 20: 1–46. [DOI] [PubMed] [Google Scholar]
  • 14. Battifora H, Gaffey M, Esteban J, Mehta P, Bailey A, Faucett C, Niland J. Immunohistochemical assay of neu/c‐erbB‐2 oncogene product in paraffin‐embedded tissues in early breast cancer: retrospective follow‐up study of 245 stage I and II cases. Mod Pathol 1991; 4: 466–74. [PubMed] [Google Scholar]
  • 15. Lupu R, Dickson RB, Lippman ME. The role of erbB‐2 and its ligands in growth control of malignant breast epithelium. J Steroid Biochem Mol Biol 1992; 43: 229–36. [DOI] [PubMed] [Google Scholar]
  • 16. Ross JS, McKenna BJ. The HER‐2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001; 19: 554–68. [DOI] [PubMed] [Google Scholar]
  • 17. Hynes NE. Amplification and overexpression of the erbB‐2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol 1993; 4: 19–26. [PubMed] [Google Scholar]
  • 18. Berchuck A. Biomarkers in the ovary. J Cell Biochem Suppl 1995; 23: 223–6. [PubMed] [Google Scholar]
  • 19. Tokunaga A, Onda M, Okuda T, Teramoto T, Fujita I, Mizutani T, Kiyama T, Yoshiyuki T, Nishi K, Matsukura N. Clinical significance of epidermal growth factor (EGF), EGF receptor, and c‐erbB‐2 in human gastric cancer. Cancer 1995; 75: 1418–25. [DOI] [PubMed] [Google Scholar]
  • 20. Besmer P, Murphy JE, George PC, Qiu FH, Bergold PJ, Lederman L, Snyder HW Jr, Brodeur D, Zuckerman EE, Hardy WD. A new acute transforming feline retrovirus and relationship of its oncogene v‐kit with the protein kinase gene family. Nature 1986; 320: 415–21. [DOI] [PubMed] [Google Scholar]
  • 21. Williams DE, Eisenman J, Baird A, Rauch C, Van Ness K, March CJ, Park LS, Martin U, Mochizuki DY, Boswell HS, Burgess GS, Cosman D, Lyman SD. Identification of a ligand for the c‐kit proto‐oncogene. Cell 1990; 63: 67–74. [DOI] [PubMed] [Google Scholar]
  • 22. Flanagan JG, Leder P. The kit ligand: a cell surface molecule altered in steel mutant fibroblasts. Cell 1990; 63: 85–94. [DOI] [PubMed] [Google Scholar]
  • 23. Zsebo KM, Williams DA, Geissler EN, Broudy VC, Martin FH, Atkins HL, Hsu RY, Birkett NC, Okino KH, Murdock DC, Jacobsen FW, Langley KE, Smith KA, Takeishi T, Cattanach BM, Galli SJ, Suggs SV. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c‐kit tyrosine kinase receptor. Cell 1990; 63: 213–24. [DOI] [PubMed] [Google Scholar]
  • 24. Russel ES, Thompson MW, McFarland E. Analysis of effects of W and f genic substitutions on fetal mouse hematology. Genetics 1968; 58: 259–70. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Kitamura Y, Go S. Decreased production of mast cells in S1/S1d anemic mice. Blood 1979; 53: 492–7. [PubMed] [Google Scholar]
  • 26. Besmer P, Manova K, Duttlinger R, Huang EJ, Packer A, Gyssler C, Bachvarova RF. The kit‐ligand (steel factor) and its receptor c‐kit/W: pleiotropic roles in gametogenesis and melanogenesis. Dev Suppl; 1993: 125–37. [PubMed] [Google Scholar]
  • 27. Huizinga JD, Thuneberg L, Kluppel M, Malysz J, Mikkelsen HB, Bernstein A. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 1995; 373: 347–9. [DOI] [PubMed] [Google Scholar]
  • 28. Miettinen M, Lasota J. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1–12. [DOI] [PubMed] [Google Scholar]
  • 29. Cheuk W, Lee KC, Chan JK. c‐kit immunocytochemical staining in the cytologic diagnosis of metastatic gastrointestinal stromal tumor. A report of two cases. Acta Cytol 2000; 44: 679–85. [DOI] [PubMed] [Google Scholar]
  • 30. Goselink HM, Williams DE, Fibbe WE, Wessels HW, Beverstock GC, Willemze R, Falkenburg JH. Effect of mast cell growth factor (c‐kit ligand) on clonogenic leukemic precursor cells. Blood 1992; 80: 750–7. [PubMed] [Google Scholar]
  • 31. Cohen PS, Chan JP, Lipkunskaya M, Biedler JL, Seeger RC. Expression of stem cell factor and c‐kit in human neuroblastoma. The Children' s Cancer Group. Blood 1994; 84: 3465–72. [PubMed] [Google Scholar]
  • 32. Tsuura Y, Hiraki H, Watanabe K, Igarashi S, Shimamura K, Fukuda T, Suzuki T, Seito T. Preferential localization of c‐kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin‐fixed, paraffin‐embedded tissues. Virchows Arch 1994; 424: 135–41. [DOI] [PubMed] [Google Scholar]
  • 33. Natali PG, Nicotra MR, Sures I, Mottolese M, Botti C, Ullrich A. Breast cancer is associated with loss of the c‐kit oncogene product. Int J Cancer 1992; 52: 713–7. [DOI] [PubMed] [Google Scholar]
  • 34. Toyota M, Hinoda Y, Takaoka A, Makiguchi Y, Takahashi T, Itoh F, Imai K, Yachi A. Expression of c‐kit and kit ligand in human colon carcinoma cells. Tumour Biol 1993; 14: 295–302. [DOI] [PubMed] [Google Scholar]
  • 35. Inoue M, Kyo S, Fujita M, Enomoto T, Kondoh G. Coexpression of the c‐kit receptor and the stem cell factor in gynecological tumors. Cancer Res 1994; 54: 3049–53. [PubMed] [Google Scholar]
  • 36. Sekido Y, Obata Y, Ueda R, Hida T, Suyama M, Shimokata K, Ariyoshi Y, Takahashi T. Preferential expression of c‐kit protooncogene transcripts in small cell lung cancer. Cancer Res 1991; 51: 2416–9. [PubMed] [Google Scholar]
  • 37. Tsuda H, Kitada S, Hasegawa T, Tani Y, Murata T, Tamai S, Hirohashi S, Matsubara O, Natori T. Frequent concurrence of expression the KIT onco‐protein and epidermal growth factor receptor overexpression in special histologic subtypes of human breast cancer. Proc Am Assoc Cancer Res 2003; 44 (2nd ed): 4449. [Google Scholar]
  • 38. Scobie JV, Acs G, Bandera CA, Blank SV, Wheeler JE, Pasha TL, Salscheider M, Zhang PJ. C‐kit immunoreactivity in endometrial adenocarcinomas and its clinicopathologic significance. Int J Gynecol Pathol 2003; 22: 149–55. [DOI] [PubMed] [Google Scholar]
  • 39. Klein WM, Kurman RJ. Lack of expression of c‐kit protein (CD117) in mesenchymal tumors of the uterus and ovary. Int J Gynecol Pathol 2003; 22: 181–4. [DOI] [PubMed] [Google Scholar]
  • 40. Berchuck A, Soisson AP, Olt GJ, Soper JT, Clarke‐Pearson DL, Bast RC Jr, McCarty KS Jr. Epidermal growth factor receptor expression in normal and malignant endometrium. Am J Obstet Gynecol 1989; 161: 1247–52. [DOI] [PubMed] [Google Scholar]
  • 41. Khakifa MA, Abdoh AA, Mannel RS, Haraway SD, Walket JL, Min KW. Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma. Cancer 1994; 73: 370–6. [DOI] [PubMed] [Google Scholar]
  • 42. Reinartz JJ, George E, Lindgren BR, Niehans GA. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c‐erbB‐2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 1994; 25: 1075–83. [DOI] [PubMed] [Google Scholar]
  • 43. Swisher EM, Gown AM, Skelly M, Ek M, Tamimi HK, Cain JM, Greer BE, Muntz HG, Goff BA. The expression of epidermal growth factor receptor, HER‐2/Neu, p53, and Ki‐67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma. Gynecol Oncol 1996; 60: 81–88. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES